Surgical Oncology, Department of Surgery, Tübingen Comprehensive Cancer Center, University of Tübingen, Germany.
Cancer Invest. 2012 Mar;30(3):209-24. doi: 10.3109/07357907.2012.654871.
Tumor involvement of the peritoneum-peritoneal carcinomatosis-is a heterogeneous form of cancer that had been generally regarded as a sign of systemic tumor disease and as a terminal condition. The multimodal treatment approach for patients with peritoneal carcinomatosis, which had been conceived and developed, consists of what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Depending on the tumor mass as assessed intraoperatively and the histopathological differentiation, patients who undergo cytoreductive surgery and HIPEC have a significant survival benefit. Mean increases in the survival period ranging from six months to up to four years have now been reported. In view of the substantial logistic effort and the extent of the surgery involved, this treatment approach represents a major challenge both for patients and for surgical oncologists, as well as for the members of the overall interdisciplinary structure required, which includes oncology, anesthesiology and intensive care, psycho-oncology, and patient management. The surgical procedures alone may take 8-14 hr. The present paper provides an overview of the basis for the approach and the use of specialized classifications and quantitative prognostic indicators.
腹膜肿瘤累及——腹膜转移癌，是一种异质性的癌症形式，通常被认为是全身性肿瘤疾病的标志和终末期情况。针对腹膜转移癌患者的多模式治疗方法，即细胞减灭术联合腹腔热灌注化疗（HIPEC），已经被设想和发展。根据术中评估的肿瘤负荷和组织病理学分化程度，接受细胞减灭术和 HIPEC 的患者具有显著的生存获益。目前报道的中位生存期延长从 6 个月到 4 年不等。鉴于巨大的后勤工作和手术范围，这种治疗方法对患者、外科肿瘤学家以及所需的多学科结构的成员（包括肿瘤学、麻醉学和重症监护、心理肿瘤学和患者管理）来说都是一个重大挑战。单纯手术就可能需要 8-14 小时。本文概述了这种方法的基础、使用的专业分类和定量预后指标。
